Tackling the persistent public health challenge of high blood pressure, Quantum Genomics has raised $6.2M to advance its novel therapeutic approach. The biopharmaceutical company is developing a new class of drugs, Brain Aminopeptidase A Inhibitors (BAPAIs), designed to control hypertension and prevent cardiovascular risks such as heart failure.
Quantum Genomics distinguishes itself as the sole biopharmaceutical research company developing therapies based on brain Aminopeptidase A inhibition. Its mid-term strategy involves forging partnership agreements with major pharmaceutical companies to bring these BAPAI products to market.


















